Topic: genetic analysis

Prelude Therapeutics

By blocking an enzyme linked to epigenetic regulation, Prelude hopes to cut off certain treatment-resistant cancers from the DNA splicing and proliferative mechanics necessary for tumor growth and survival.

Maze Therapeutics

Rather than targeting gene-gene interactions that kill cells, Maze is going after genetic combinations that stop people from developing deleterious phenotypes.

Black Diamond Therapeutics

Versant Ventures launched Black Diamond in December 2018 with $20 million to go after an overlooked group of oncogenes, or mutated forms of genes that can drive cancer. A month later, the company picked up another $85 million to move its lead program into the clinic in early 2020.